[go: up one dir, main page]

WO1998042324A3 - Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors - Google Patents

Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors Download PDF

Info

Publication number
WO1998042324A3
WO1998042324A3 PCT/US1998/005623 US9805623W WO9842324A3 WO 1998042324 A3 WO1998042324 A3 WO 1998042324A3 US 9805623 W US9805623 W US 9805623W WO 9842324 A3 WO9842324 A3 WO 9842324A3
Authority
WO
WIPO (PCT)
Prior art keywords
reductase inhibitors
methods
aldose reductase
neurotrophic factor
associated activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/005623
Other languages
French (fr)
Other versions
WO1998042324A2 (en
WO1998042324A9 (en
Inventor
Frank Longo
Andrew Mizisin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/045,194 external-priority patent/US6696407B1/en
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to AU64738/98A priority Critical patent/AU6473898A/en
Publication of WO1998042324A2 publication Critical patent/WO1998042324A2/en
Publication of WO1998042324A3 publication Critical patent/WO1998042324A3/en
Publication of WO1998042324A9 publication Critical patent/WO1998042324A9/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods of modulating neurotrophic factor-associated activity, especially CNTF-associated levels and activity, using aldose reductase inhibitors. These methods are especially useful in individuals suffering from, or at risk of developing, neurological disorders, including neurodegenerative disorders. The invention also provides methods of palliating neurological disorders and delaying development of neurological disorders using aldose reductase inhibitors.
PCT/US1998/005623 1997-03-21 1998-03-23 Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors Ceased WO1998042324A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU64738/98A AU6473898A (en) 1997-03-21 1998-03-23 Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82210397A 1997-03-21 1997-03-21
US08/822,103 1997-03-21
US09/045,194 1998-03-20
US09/045,194 US6696407B1 (en) 1997-03-21 1998-03-20 Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF

Publications (3)

Publication Number Publication Date
WO1998042324A2 WO1998042324A2 (en) 1998-10-01
WO1998042324A3 true WO1998042324A3 (en) 1999-01-21
WO1998042324A9 WO1998042324A9 (en) 1999-03-18

Family

ID=26722480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/005623 Ceased WO1998042324A2 (en) 1997-03-21 1998-03-23 Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors

Country Status (2)

Country Link
AU (1) AU6473898A (en)
WO (1) WO1998042324A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022531466A (en) 2019-05-07 2022-07-06 ユニバーシティ オブ マイアミ Treatment and detection of hereditary neuropathy and related disorders
CN115996725A (en) * 2020-05-01 2023-04-21 应用治疗公司 Aldose reductase inhibitors for the treatment of sorbitol dehydrogenase deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002895A1 (en) * 1977-12-29 1979-07-11 Imperial Chemical Industries Plc Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture
EP0059596A1 (en) * 1981-03-02 1982-09-08 Ayerst, Mckenna And Harrison Inc. N-Naphthoylglycine derivatives
WO1992016544A1 (en) * 1991-03-21 1992-10-01 Parfums Christian Dior Novel derivative of caffeic acid, oraposide, cosmetic or pharmaceutical, particularly dermatological, composition containing it

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002895A1 (en) * 1977-12-29 1979-07-11 Imperial Chemical Industries Plc Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture
EP0059596A1 (en) * 1981-03-02 1982-09-08 Ayerst, Mckenna And Harrison Inc. N-Naphthoylglycine derivatives
WO1992016544A1 (en) * 1991-03-21 1992-10-01 Parfums Christian Dior Novel derivative of caffeic acid, oraposide, cosmetic or pharmaceutical, particularly dermatological, composition containing it

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
A.A.F. SIMA ET AL.: "PREVENTIVE EFFECT OF LONG-TERM ALDOSE REDUCTASE INHIBITION (PONALRESTAT) ON NERVE CONDUCTION AND SURAL NERVE STRUCTURE IN THE SPONTANEOUSLY DIABETIC BIO-BREEDING RAT", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 85, no. 5, 1990, pages 1410 - 1420, XP002081353 *
A.P. MIZISIN ET AL.: "ALDOSE REDUCTASE INHIBITION INCREASES CNTF-LIKE BIOACTIVITY AND PROTEIN IN SCIATIC NERVES FROM GALACTOSE-FED AND NORMAL RATS", DIABETES, vol. 46, no. 4, April 1997 (1997-04-01), pages 647 - 652, XP002081349 *
A.P. MIZISIN ET AL.: "SCHWANN CELL INJURY IS ATTENUATED BY ALDOSE REDUCTASE INHIBITION IN GALACTOSE INTOXICATION", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, vol. 52, no. 1, 1993, pages 78 - 86, XP002081350 *
D.A. GREENE ET AL.: "EFFECTS OF ALDOSE REDUCTASE INHIBITORS ON THE PROGRESSION OF NERVE DAMAGE", DIABETIC MEDICINE, vol. 10, no. S2, 1993, pages 31S - 32S, XP002081352 *
D.F. EMERICH ET AL.: "IMPLANTS OF ENCAPSULATED HUMAN CNTF-PRODUCING FIBROBLASTS PREVENT BEHAVIORAL DEFICIT AND STRIATAL DEGENERATION IN A RODENT MODEL OF HUNTINGTON'S DISEASE", THE JOURNAL OF NEUROSCIENCE, vol. 16, no. 16, 1996, pages 5168 - 5181, XP002081356 *
D.R. TOMLINSON ET AL.: "ALDOSE REDUCTASE INHIBITORS AND DIABETIC COMPLICATIONS", PHARMACOLOGY & THERAPEUTICS, vol. 54, no. 2, 1992, pages 151 - 194, XP002081358 *
F. DITTRICH ET AL.: "CILIARY NEUROTROPHIC FACTOR: PHARMACOKINETICS AND ACUTE-PHASE RESPONSE IN RAT", ANNALS OF NEUROLOGY, vol. 35, no. 2, 1994, pages 151 - 163, XP002081357 *
J.B. JASPAN ET AL.: "CLINICAL STUDIES WITH AN ALDOSE REDUCTASE INHIBITOR IN THE AUTONOMIC AND SOMATIC NEUROPATHIES OF DIABETES", METABOLISM, vol. 35, no. 4, 1986, pages 83 - 92, XP002081354 *
M. TERADA ET AL.: "TOLRESTAT IMPROVES NERVE REGENERATION AFTER CRUSH INJURY IN STREPTOZOCIN-INDUCED DIABETIC RATS", METABOLISM, vol. 45, no. 10, pages 1189 - 1195, XP002081351 *
N.A. CALCUTT ET AL.: "REDUCED CILIARY NEURONOTROPHIC FACTOR-LIKE ACTIVITY IN NERVES FROM DIABETIC OR GALACTOSE-FED RATS", BRAIN RESEARCH, vol. 575, no. 2, 1992, pages 320 - 324, XP002081355 *

Also Published As

Publication number Publication date
WO1998042324A2 (en) 1998-10-01
AU6473898A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
EP1247803A3 (en) Indolinone compounds suitable for modulation of protein kinases
WO2002069900A3 (en) Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
WO2002099054A3 (en) Hccss as modifiers of the p53 pathway and methods of use
WO2003002717A3 (en) Biological activity of ak155
AU5801199A (en) Bottom or top jumpered foldable electronic assembly, and method for manufacture
WO2002098899A3 (en) CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004028454A3 (en) 1, 3, 5-triazines for treatment of viral diseases
WO2001006989A3 (en) Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
AU2396000A (en) Treatment of hyperproliferative disorders using casein kinase
AU9214498A (en) Treatment of attention-deficit/hyperactivity disorder
WO1999025843A3 (en) Human checkpoint kinase, hcds1, compositions and methods
HK1039342A1 (en) Connective tissue growth factor (ctgf) and methods of use
WO1999019513A3 (en) Methods for detecting compounds which modulate the activity of an lpa receptor
WO2001098279A3 (en) Bis-arylsulfones
AU6249899A (en) System for dynamic registration, evaluation, and correction of functional human behavior
ZA200203253B (en) Methods and kits for treating depression or preventing deterioration of cognitive function.
WO2002073208A3 (en) Anti-epileptogenic agents
WO2002055663A3 (en) Srebp pathway modulation through targeting hisrs
WO2002083651A3 (en) Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
WO2000006083A3 (en) Sulfonamide derivatives
AU2384500A (en) Compounds, methods of screening and methods of treatment for central and peripheral nervous system disorders
ZA9811537B (en) Methods for regulating phagocytosis.
AU5198898A (en) Method for treatment of glutamate related disorders
WO1998042324A3 (en) Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
AU2002304931A1 (en) Methods for treating disorders of the nervous and reproductive systems

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/5-5/5; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998545863

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA